BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Segovia-Mendoza M, Morales-Montor J. Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology. Front Immunol 2019;10:348. [PMID: 30881360 DOI: 10.3389/fimmu.2019.00348] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Onkar SS, Carleton NM, Lucas PC, Bruno TC, Lee AV, Vignali DAA, Oesterreich S. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov 2023;13:23-40. [PMID: 36620880 DOI: 10.1158/2159-8290.CD-22-0475] [Reference Citation Analysis]
2 Tramice A, Paris D, Manca A, Guevara Agudelo FA, Petrosino S, Siracusa L, Carbone M, Melck D, Raymond F, Piscitelli F. Analysis of the oral microbiome during hormonal cycle and its alterations in menopausal women: the "AMICA" project. Sci Rep 2022;12:22086. [PMID: 36543896 DOI: 10.1038/s41598-022-26528-w] [Reference Citation Analysis]
3 Ratre P, Kulkarni S, Das S, Liang C, Mishra PK, Thareja S. Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview. Med Oncol 2022;40:41. [PMID: 36471176 DOI: 10.1007/s12032-022-01916-4] [Reference Citation Analysis]
4 Halim F, Azhar Y, Suwarman S, Hernowo B. p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer. F1000Res 2022;11:330. [PMID: 36519010 DOI: 10.12688/f1000research.108628.2] [Reference Citation Analysis]
5 Halim F, Azhar Y, Suwarman S, Hernowo B. p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer. F1000Res 2022;11:330. [PMID: 36519010 DOI: 10.12688/f1000research.108628.2] [Reference Citation Analysis]
6 Niveria K, Yadav M, Dangi K, Verma AK. Overcoming challenges to enable targeting of metastatic breast cancer tumour microenvironment with nano-therapeutics: Current status and future perspectives. OpenNano 2022;8:100083. [DOI: 10.1016/j.onano.2022.100083] [Reference Citation Analysis]
7 Nicolini A, Ferrari P, Carpi A. Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. Biomedicines 2022;10:2511. [PMID: 36289773 DOI: 10.3390/biomedicines10102511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Armerinayanti NW, Widodo S, Oki Lestari DP. Matrix Metalloproteinase 9 Expression by Immunohistochemistry in Intratumor Macrophages as Tumor-Associated Macrophage Marker of Papillary Thyroid Carcinoma. Biomed Pharmacol J 2022;15:1671-1676. [DOI: 10.13005/bpj/2505] [Reference Citation Analysis]
9 Shahverdi M, Masoumi J, Ghorbaninezhad F, Shajari N, Hajizadeh F, Hassanian H, Alizadeh N, Jafarlou M, Baradaran B. The modulatory role of dendritic cell-T cell cross-talk in breast cancer: Challenges and prospects. Adv Med Sci 2022;67:353-63. [PMID: 36116207 DOI: 10.1016/j.advms.2022.09.001] [Reference Citation Analysis]
10 Shankar Narayan S, Vaishnaw NS, Shivakumar BN, Vaishnav A. Computational Simulation of the Effect of Increase in the Estrogen level on the Normal- Tumour- Immune- Unhealthy Diet Model for breast cancer. J Phys : Conf Ser 2022;2332:012020. [DOI: 10.1088/1742-6596/2332/1/012020] [Reference Citation Analysis]
11 Cui W, Phillips K, Francis PA, Anderson RA, Partridge AH, Loi S, Loibl S, Keogh L. Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. The Breast 2022;64:56-62. [DOI: 10.1016/j.breast.2022.05.002] [Reference Citation Analysis]
12 Becerril Alarcón Y, Bastida González F, Camacho Beiza IR, Dávila González E, Cruz Ramos JA, Benítez Arciniega AD, Valdés Ramos R, Soto Piña AE. Association of GSTT1, GSTM1 and GSTP1 (Ile105Val) mRNA Expression with Cardiometabolic Risk Parameters in Women with Breast Cancer and Comorbidities. Cardiogenetics 2022;12:235-245. [DOI: 10.3390/cardiogenetics12030022] [Reference Citation Analysis]
13 Vathiotis IA, Trontzas I, Gavrielatou N, Gomatou G, Syrigos NK, Kotteas EA. Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives. Clin Breast Cancer 2022:S1526-8209(22)00140-9. [PMID: 35906130 DOI: 10.1016/j.clbc.2022.06.004] [Reference Citation Analysis]
14 Takeshita T, Tokumaru Y, Oshi M, Wu R, Patel A, Tian W, Hatanaka Y, Hatanaka KC, Yan L, Takabe K. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. Front Oncol 2022;12:865024. [PMID: 35677163 DOI: 10.3389/fonc.2022.865024] [Reference Citation Analysis]
15 Stukan AI, Goryainova AY, Meshcheryakov AA, Porkhanov VA, Murashko RA, Sharov SV, Bodnya VN. Dynamic changes in the tumor microenvironment under the effect of estradiol as a diagnostic tool and target for targeted cancer therapy. Bûll sib med 2022;21:171-182. [DOI: 10.20538/1682-0363-2022-1-171-182] [Reference Citation Analysis]
16 Tong D. Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment. J Immunother Cancer 2022;10:e002944. [PMID: 35383112 DOI: 10.1136/jitc-2021-002944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Costa B, Vale N. Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer. Int J Mol Sci 2022;23:3181. [PMID: 35328602 DOI: 10.3390/ijms23063181] [Reference Citation Analysis]
18 Nava-castro KE, Pavón L, Becerril-villanueva LE, Ponce-regalado MD, Aguilar-díaz H, Segovia-mendoza M, Morales-montor J. Sexual Dimorphism of the Neuroimmunoendocrine Response in the Spleen during a Helminth Infection: A New Role for an Old Player? Pathogens 2022;11:308. [DOI: 10.3390/pathogens11030308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mohammad Mirzaei N, Changizi N, Asadpoure A, Su S, Sofia D, Tatarova Z, Zervantonakis IK, Chang YH, Shahriyari L. Investigating key cell types and molecules dynamics in PyMT mice model of breast cancer through a mathematical model. PLoS Comput Biol 2022;18:e1009953. [PMID: 35294447 DOI: 10.1371/journal.pcbi.1009953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Palacios-Arreola MI, Moreno-Mendoza NA, Nava-Castro KE, Segovia-Mendoza M, Perez-Torres A, Garay-Canales CA, Morales-Montor J. The Endocrine Disruptor Compound Bisphenol-A (BPA) Regulates the Intra-Tumoral Immune Microenvironment and Increases Lung Metastasis in an Experimental Model of Breast Cancer. Int J Mol Sci 2022;23:2523. [PMID: 35269666 DOI: 10.3390/ijms23052523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Segovia-Mendoza M, Palacios-Arreola MI, Pavón L, Becerril LE, Nava-Castro KE, Amador-Muñoz O, Morales-Montor J. Environmental Pollution to Blame for Depressive Disorder? Int J Environ Res Public Health 2022;19:1737. [PMID: 35162759 DOI: 10.3390/ijerph19031737] [Reference Citation Analysis]
22 Čelešnik H, Potočnik U. Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer. Cancers (Basel) 2022;14:591. [PMID: 35158858 DOI: 10.3390/cancers14030591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Tan C, Zuo F, Lu M, Chen S, Tian Z, Hu Y. Identification of potential genes correlated with breast cancer metastasis and prognosis. All Life 2022;15:126-33. [DOI: 10.1080/26895293.2021.2021302] [Reference Citation Analysis]
24 Mir MA, Haq BU. Targeting tumor microenvironment for breast cancer treatment. Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies 2022. [DOI: 10.1016/b978-0-443-18696-7.00008-7] [Reference Citation Analysis]
25 Mir MA, Aisha S, Sofi S, Rasheid S. The tumor microenvironment. Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies 2022. [DOI: 10.1016/b978-0-443-18696-7.00007-5] [Reference Citation Analysis]
26 Segovia-mendoza M, Fernández-lópez BE, Lemini C, Carlos-reyes A, Prado-garcia H. Role of Membrane Estrogen Receptor (GPER1) on the Function of Immune Cells and Its Consequences on Breast Cancer Pathophysiology. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_48] [Reference Citation Analysis]
27 Maharjan CK, Mo J, Wang L, Kim MC, Wang S, Borcherding N, Vikas P, Zhang W. Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer. Cancers (Basel) 2021;14:206. [PMID: 35008370 DOI: 10.3390/cancers14010206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Ye Y, Xu C, Chen F, Liu Q, Cheng N. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review. Front Immunol 2021;12:771201. [PMID: 34899721 DOI: 10.3389/fimmu.2021.771201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Retecki K, Seweryn M, Graczyk-Jarzynka A, Bajor M. The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers (Basel) 2021;13:6012. [PMID: 34885122 DOI: 10.3390/cancers13236012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
30 Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Mohammad Mirzaei N, Su S, Sofia D, Hegarty M, Abdel-Rahman MH, Asadpoure A, Cebulla CM, Chang YH, Hao W, Jackson PR, Lee AV, Stover DG, Tatarova Z, Zervantonakis IK, Shahriyari L. A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. J Pers Med 2021;11:1031. [PMID: 34683171 DOI: 10.3390/jpm11101031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
32 Chen Y, Xia F, Jiang B, Wang W, Li X. Role of Immune Cell-Specific Hypermethylation Signatures in Classification and Risk Stratification of Breast Cancer. Front Med (Lausanne) 2021;8:674338. [PMID: 34513864 DOI: 10.3389/fmed.2021.674338] [Reference Citation Analysis]
33 Li JJ, Tsang JY, Tse GM. Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel) 2021;13:4233. [PMID: 34439387 DOI: 10.3390/cancers13164233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
34 Jiang L, Fei H, Yang A, Zhu J, Sun J, Liu X, Xu W, Yang J, Zhang S. Estrogen inhibits the growth of colon cancer in mice through reversing extracellular vesicle-mediated immunosuppressive tumor microenvironment. Cancer Lett 2021;520:332-43. [PMID: 34391809 DOI: 10.1016/j.canlet.2021.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hassani H, Machado JAT, Avazzadeh Z, Safari E, Mehrabi S. Optimal solution of the fractional order breast cancer competition model. Sci Rep 2021;11:15622. [PMID: 34341390 DOI: 10.1038/s41598-021-94875-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Haines CN, Wardell SE, McDonnell DP. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. Essays Biochem 2021:EBC20200174. [PMID: 34328178 DOI: 10.1042/EBC20200174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Schuler LA, Murdoch FE. Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. Cancers (Basel) 2021;13:3725. [PMID: 34359625 DOI: 10.3390/cancers13153725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Badve SS, Penault-Llorca F, Reis-Filho JS, Deurloo R, Siziopikou KP, D'Arrigo C, Viale G. Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130. J Natl Cancer Inst 2021:djab121. [PMID: 34286340 DOI: 10.1093/jnci/djab121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
39 Curran CS, Ponik SM. The Mammary Tumor Microenvironment. Adv Exp Med Biol 2020;1296:163-81. [PMID: 34185292 DOI: 10.1007/978-3-030-59038-3_10] [Reference Citation Analysis]
40 Moccia C, Haase K. Engineering Breast Cancer On-chip-Moving Toward Subtype Specific Models. Front Bioeng Biotechnol 2021;9:694218. [PMID: 34249889 DOI: 10.3389/fbioe.2021.694218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Mathias C, Muzzi JCD, Antunes BB, Gradia DF, Castro MAA, Carvalho de Oliveira J. Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes. Front Oncol 2021;11:692170. [PMID: 34136413 DOI: 10.3389/fonc.2021.692170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
42 Missiroli S, Perrone M, Boncompagni C, Borghi C, Campagnaro A, Marchetti F, Anania G, Greco P, Fiorica F, Pinton P, Giorgi C. Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer. Cancers (Basel) 2021;13:2297. [PMID: 34064909 DOI: 10.3390/cancers13102297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
43 Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol 2021;11:610303. [PMID: 33777750 DOI: 10.3389/fonc.2021.610303] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 21.5] [Reference Citation Analysis]
44 Malherbe K. Tumor Microenvironment and the Role of Artificial Intelligence in Breast Cancer Detection and Prognosis. Am J Pathol 2021;191:1364-73. [PMID: 33639101 DOI: 10.1016/j.ajpath.2021.01.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Khella CA, Mehta GA, Mehta RN, Gatza ML. Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. J Pers Med 2021;11:149. [PMID: 33669749 DOI: 10.3390/jpm11020149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
46 Teng NMY, Price CA, McKee AM, Hall LJ, Robinson SD. Exploring the impact of gut microbiota and diet on breast cancer risk and progression. Int J Cancer 2021;149:494-504. [PMID: 33521932 DOI: 10.1002/ijc.33496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
47 Wu D, Zhao Z, Kim J, Razmi A, Wang LL, Kapate N, Gao Y, Peng K, Ukidve A, Mitragotri S. Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer. Bioeng Transl Med 2021;6:e10188. [PMID: 33532588 DOI: 10.1002/btm2.10188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
48 Fouad MA, Sayed-Ahmed MM, Huwait EA, Hafez HF, Osman AM. Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells. BMC Pharmacol Toxicol 2021;22:8. [PMID: 33509300 DOI: 10.1186/s40360-021-00473-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Segovia-Mendoza M, Romero-Garcia S, Lemini C, Prado-Garcia H. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. J Immunol Res 2021;2021:6668573. [PMID: 33506060 DOI: 10.1155/2021/6668573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
50 Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, Ni C. The immunomodulatory effects of endocrine therapy in breast cancer. J Exp Clin Cancer Res 2021;40:19. [PMID: 33413549 DOI: 10.1186/s13046-020-01788-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
51 Moradi Tabriz H, Obohat M, Vahedifard F, Eftekharjavadi A. Survey of Mast Cell Density in Transitional Cell Carcinoma. Iran J Pathol 2021;16:119-27. [PMID: 33936222 DOI: 10.30699/IJP.2020.123562.2345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
52 Lee YT, Chuang YM, Chan MWY. Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. Epigenomes 2020;4:27. [PMID: 34968306 DOI: 10.3390/epigenomes4040027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
53 Hematian Larki M, Barani S, Talei AR, Ghaderi A. Diversity of KIRs in invasive breast cancer patients and healthy controls along with the clinical significance in ER/PR/HER2+ patients. Genes Immun 2020;21:380-9. [PMID: 33257819 DOI: 10.1038/s41435-020-00117-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
54 Ye Q, Han X, Wu Z. Bioinformatics analysis to screen key prognostic genes in the breast cancer tumor microenvironment. Bioengineered 2020;11:1280-300. [PMID: 33164640 DOI: 10.1080/21655979.2020.1840731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
55 Rusch P, Hirner AV, Schmitz O, Kimmig R, Hoffmann O, Diel M. Zinc distribution within breast cancer tissue of different intrinsic subtypes. Arch Gynecol Obstet 2021;303:195-205. [PMID: 32930875 DOI: 10.1007/s00404-020-05789-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
56 Lawson JT, Smith JP, Bekiranov S, Garrett-Bakelman FE, Sheffield NC. COCOA: coordinate covariation analysis of epigenetic heterogeneity. Genome Biol 2020;21:240. [PMID: 32894181 DOI: 10.1186/s13059-020-02139-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
57 Segovia-Mendoza M, Nava-Castro KE, Palacios-Arreola MI, Garay-Canales C, Morales-Montor J. How microplastic components influence the immune system and impact on children health: Focus on cancer. Birth Defects Res 2020;112:1341-61. [PMID: 32767490 DOI: 10.1002/bdr2.1779] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
58 Lawson JT, Smith JP, Bekiranov S, Garrett-bakelman FE, Sheffield NC. COCOA: Coordinate covariation analysis of epigenetic heterogeneity.. [DOI: 10.1101/2020.07.09.195289] [Reference Citation Analysis]
59 Goff SL, Danforth DN. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. Clin Breast Cancer 2021;21:e63-73. [PMID: 32893093 DOI: 10.1016/j.clbc.2020.06.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
60 Hu C, Liu Y, Jiang S, Chen H, Xu H, Hu J, Li C, Xia H. The variable association between expression and methylation of estrogen receptors and the survival of patients with different tumors. Clin Transl Med 2020;10:e49. [PMID: 32536040 DOI: 10.1002/ctm2.49] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Shanmugaraj B, Priya LB, Mahalakshmi B, Subbiah S, Hu R, Velmurugan BK, Baskaran R. Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy. Life Sciences 2020;250:117550. [DOI: 10.1016/j.lfs.2020.117550] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
62 Wu X, Sun A, Yu W, Hong C, Liu Z. CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation. Mol Cell Endocrinol 2020;512:110866. [PMID: 32417506 DOI: 10.1016/j.mce.2020.110866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
63 Serpico AF, Visconti R, Grieco D. Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death Dis 2020;11:361. [PMID: 32398657 DOI: 10.1038/s41419-020-2567-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
64 Smith L, Parris C, Veronese N, Shang C, López-Sánchez GF, Jacob L, Koyanagi A, Nottegar A, Jackson SE, Raupach T, Grabovac I, Crichton S, Dempsey F, Yang L. Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults. Clin Exp Med 2020;20:409-16. [PMID: 32219665 DOI: 10.1007/s10238-020-00622-7] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Li W, Sang M, Hao X, Jia L, Wang Y, Shan B. Gene expression and DNA methylation analyses suggest that immune process-related ADCY6 is a prognostic factor of luminal-like breast cancer. J Cell Biochem 2020;121:3537-46. [PMID: 31886586 DOI: 10.1002/jcb.29633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
66 Kim H, Kim DW, Cho JY. Exploring the key communicator role of exosomes in cancer microenvironment through proteomics. Proteome Sci 2019;17:5. [PMID: 31686989 DOI: 10.1186/s12953-019-0154-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
67 Barriga V, Kuol N, Nurgali K, Apostolopoulos V. The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. Cancers (Basel) 2019;11:E1205. [PMID: 31430935 DOI: 10.3390/cancers11081205] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]